Log in to search using one of your social media accounts:

 

PAX3-FOXO1: Zooming in on an “undruggable” target
Publication date: Available online 14 November 2017 Source:Seminars in Cancer Biology Author(s): Marco Wachtel, Beat W. Schäfer Driver oncogenes are prime targets for therapy in tumors many of which, including leukemias and sarcomas, express recurrent fusion transcription factors. One specific example for such a cancer type is alveolar rhabdomyosarcoma, which is associated in the majority of cases with the fusion protein PAX3-FOXO1. Since fusion transcription factors are challenging targets for development of small molecule inhibitors, indirect inhibitory strategies for this type of oncogenes represent a more promisi...
Source: Seminars in Cancer Biology - November 14, 2017 Category: Cancer & Oncology Source Type: research

Dna-hypomethylating agents as epigenetic therapy before and after allogeneic hematopoietic stem cell transplantation in myelodysplastic syndromes and juvenile myelomonocytic leukemia
Publication date: Available online 9 November 2017 Source:Seminars in Cancer Biology Author(s): Christian Flotho, Sebastian Sommer, Michael Lübbert Myelodysplastic syndrome (MDS) is a clonal bone marrow disorder, typically of older adults, which is characterized by ineffective hematopoiesis, peripheral blood cytopenias and risk of progression to acute myeloid leukemia. Juvenile myelomonocytic leukemia (JMML) is an aggressive myeloproliferative neoplasm occurring in young children. The common denominator of these malignant myeloid disorders is the limited benefit of conventional chemotherapy and a particular responsiv...
Source: Seminars in Cancer Biology - November 10, 2017 Category: Cancer & Oncology Source Type: research

Enzymes involved in tumor-driven angiogenesis: a valuable target for anticancer therapy
Publication date: Available online 8 November 2017 Source:Seminars in Cancer Biology Author(s): Biagio Ricciuti, Jennifer Foglietta, Vanessa Bianconi, Amirhossein Sahebkar, Matteo Pirro Angiogenesis plays a pivotal role in cancer progression and is required for tissue invasion and metastasis. Starting with Folkman’s initial observations in 1971, basic research continued to shed new molecular insight into this multifaceted process, leading to the development of several anti-angiogenic drugs. To date, anti-vascular endothelial growth factor monoclonal antibodies, such as bevacizumab and ramucirumab, and receptor tyros...
Source: Seminars in Cancer Biology - November 9, 2017 Category: Cancer & Oncology Source Type: research

Molecular and enzoinformatics perspectives of targeting Polo-like kinase 1 in cancer therapy
Publication date: Available online 6 November 2017 Source:Seminars in Cancer Biology Author(s): Shazi Shakil, Mohammad H. Baig, Shams Tabrez, Syed M. Danish Rizvi, Syed K. Zaidi, Ghulam M. Ashraf, Shakeel A. Ansari, Aftab Aslam Parwaz Khan, Mohammad H. Al-Qahtani, Adel M. Abuzenadah, Adeel G. Chaudhary Cancer is a disease that has been the focus of scientific research and discovery and continues to remain so. Polo-like kinases (PLKs) are basically serine/threonine kinase enzymes that control cell cycle from yeast to humans. PLK-1 stands for ‘Polo-like kinase-1’. It is the most investigated protein among PLKs. ...
Source: Seminars in Cancer Biology - November 7, 2017 Category: Cancer & Oncology Source Type: research

Breast cancer genomics and immuno-oncological markers to guide immune therapies
Publication date: Available online 2 November 2017 Source:Seminars in Cancer Biology Author(s): D. Hammerl, M. Smid, A.M. Timmermans, S. Sleijfer, J.W.M. Martens, R. Debets There is an increasing awareness of the importance of tumor – immune cell interactions to the evolution and therapy responses of breast cancer (BC). Not surprisingly, numerous studies are currently assessing the clinical value of immune modulation for BC patients. However, till now durable clinical responses are only rarely observed. It is important to realize that BC is a heterogeneous disease comprising several histological and molecular subtyp...
Source: Seminars in Cancer Biology - November 6, 2017 Category: Cancer & Oncology Source Type: research

Do all roads lead to the Rome? The glycation perspective!
Publication date: Available online 4 November 2017 Source:Seminars in Cancer Biology Author(s): Saheem Ahmad, Firoz Akhter, Uzma Shahab, Zeeshan Rafi, Mohd. Sajid Khan, Rabia Nabi, Mohd Salman Khan, Khurshid Ahmad, Jalaluddin Mohammad Ashraf, Moinuddin Oxidative, carbonyl, and glycative stress have gained substantial attention recently for their alleged influence on cancer progression. Oxidative stress can trigger variable transcription factors, such as nuclear factor erythroid-2-related factor (Nrf2), nuclear factor kappa B (NF-κB), protein-53 (p-53), activating protein-1 (AP-1), hypoxia-inducible factor-1α (...
Source: Seminars in Cancer Biology - November 5, 2017 Category: Cancer & Oncology Source Type: research

Vitamin C – a new player in regulation of the cancer epigenome
Publication date: Available online 1 November 2017 Source:Seminars in Cancer Biology Author(s): Linn Gillberg, Andreas D. Ørskov, Minmin Liu, Laurine B.S. Harsløf, Peter A. Jones, Kirsten Grønbæk Over the past few years it has become clear that vitamin C, as a provider of reduced iron, is an essential factor for the function of epigenetic regulators that initiate the demethylation of DNA and histones. Vitamin C deficiency is rare in the general population, but is frequently observed in patients with cancer. Genes encoding epigenetic regulators are often mutated in cancer, underscoring their cent...
Source: Seminars in Cancer Biology - November 3, 2017 Category: Cancer & Oncology Source Type: research

Current insights into functions of phospholipase A2 receptor in normal and cancer cells: More questions than answers
Publication date: Available online 2 November 2017 Source:Seminars in Cancer Biology Author(s): Olga Sukocheva, Mario Menschikowski, Albert Hagelgans, Nagendra Sastry Yarla, Gabriele Siegert, Pallu Reddanna, Anupam Bishayee Lipid signaling network was proposed as a potential target for cancer prevention and treatment. Several recent studies revealed that phospholipid metabolising enzyme, phospholipase A2 (PLA2), is a critical regulator of cancer accelerating pathologies and apoptosis in several types of cancers. In addition to functioning as an enzyme, PLA2 can activate a phospholipase A2 receptor (PLA2R1) in plasma membr...
Source: Seminars in Cancer Biology - November 3, 2017 Category: Cancer & Oncology Source Type: research

Implications of farnesyltransferase and its inhibitors as a promising strategy for cancer therapy
Publication date: Available online 31 October 2017 Source:Seminars in Cancer Biology Author(s): Sergey G. Klochkov, Margarita E. Neganova, Nagendra Sastry Yarla, Madhukiran Parvathaneni, Bechan Sharma, Vadim V. Tarasov, George Barreto, Sergey O. Bachurin, Ghulam Md Ashraf, Gjumrakch Aliev Ras proteins have been reported to play key role in oncologic diseases. Ras proteins are associated with cellular membranes for its carcinogenic activities through post-translational modifications, including farnesylation. Farnesyltransferase is responsible for a type of Ras membrane targeting, which leads to cancer origin and progressio...
Source: Seminars in Cancer Biology - October 31, 2017 Category: Cancer & Oncology Source Type: research

The role of dietary pattern, foods, nutrients and nutraceuticals in supporting cancer prevention and treatment
Publication date: October 2017 Source:Seminars in Cancer Biology, Volume 46 (Source: Seminars in Cancer Biology)
Source: Seminars in Cancer Biology - October 30, 2017 Category: Cancer & Oncology Source Type: research

Oxidation, glycation and glycoxidation —The vicious cycle and lung cancer
Publication date: Available online 19 October 2017 Source:Seminars in Cancer Biology Author(s): Saheem Ahmad, Mohd Yasir Khan, Zeeshan Rafi, Hamda Khan, Zeba Siddiqui, Shahnawaz Rehman, Uzma Shahab, Mohd Sajid Khan, Mohd Saeed, Sultan Alouffi, Mohd Shahnawaz Khan The combine effect of oxidative and glycative stress predisposed to glycoxidation, and their outcomes that play critical role in lung cancer have been examined in different ways. The therapeutic approaches for lung cancer are still unsatisfactory. We observe some unclear and decisive pathways which might play an important role in targeting lung cancer. The roadma...
Source: Seminars in Cancer Biology - October 30, 2017 Category: Cancer & Oncology Source Type: research

Epigenetics of Malignant Melanoma
Publication date: Available online 23 October 2017 Source:Seminars in Cancer Biology Author(s): Bruce Moran, Romina Silva, Antoinette S. Perry, William M. Gallagher Patients with malignant melanoma generally have a good prognosis if the disease presents prior to metastasis. Due to progress with targeted and immunotherapies, the median survival of metastatic melanoma patients is now over 2 years. The disease is characterised by one of the highest somatic mutation rates observed amongst cancer types, with a specific mutational signature based on UV radiation damage evident. Highly prevalent mutations, such as the BRAFV600E ...
Source: Seminars in Cancer Biology - October 30, 2017 Category: Cancer & Oncology Source Type: research

Ousting RAGE in melanoma: A viable therapeutic target?
Publication date: Available online 24 October 2017 Source:Seminars in Cancer Biology Author(s): Deeba N. Syed, Ahmed Aljohani, Durdana Waseem, Hasan Mukhtar Melanoma remains an important health concern, given the steady increase in incidence and acquisition of resistance to systemic therapies. The receptor for advanced glycation end products (RAGE) initially identified for its binding to advanced glycation end products was subsequently acknowledged as a pattern recognition receptor given its ability to recognize similar structural elements within numerous ligands. Recent studies have elucidated a plausible role of RAGE in...
Source: Seminars in Cancer Biology - October 30, 2017 Category: Cancer & Oncology Source Type: research

KRAS, YAP, and obesity in pancreatic cancer: a signaling network with multiple loops
Publication date: Available online 24 October 2017 Source:Seminars in Cancer Biology Author(s): Guido Eibl, Enrique Rozengurt Pancreatic ductal adenocarcinoma (PDAC) continues to be a lethal disease with no efficacious treatment modalities. The incidence of PDAC is expected to increase, at least partially because of the obesity epidemic. Increased efforts to prevent or intercept this disease are clearly needed. Mutations in KRAS are initiating events in pancreatic carcinogenesis supported by genetically engineered mouse models of the disease. However, oncogenic KRAS is not entirely sufficient for the development of fully ...
Source: Seminars in Cancer Biology - October 30, 2017 Category: Cancer & Oncology Source Type: research

Genito-urinary genomics and emerging biomarkers for immunomodulatory cancer treatment
Publication date: Available online 12 October 2017 Source:Seminars in Cancer Biology Author(s): Thomas Gevaert, Rodolfo Montironi, Antonio Lopez-Beltran, Arno Van Leenders, Yves Allory, Dirk De Ridder, Frank Claessens, Mark Kockx, Murat Akand, Steven Joniau, George Netto, Louis Libbrecht Immunotherapy is gradually becoming a key factor in the therapeutic algorithm for patients with genito-urinary (GU) cancers at different stages of disease. Robust and reliable biomarkers are crucial for an appropriate inclusion of patients in clinical trials and for a reliable patient selection for treatments with immunomodulatory drugs. ...
Source: Seminars in Cancer Biology - October 12, 2017 Category: Cancer & Oncology Source Type: research

Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: a report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer
Publication date: Available online 9 October 2017 Source:Seminars in Cancer Biology Author(s): Maria Vittoria Dieci, Nina Radosevic-Robin, Susan Fineberg, Gert van den Eynden, Nils Ternes, Frederique Penault-Llorca, Giancarlo Pruneri, Timothy M. D’Alfonso, Sandra Demaria, Carlos Castaneda, Joselyn Sanchez, Sunil Badve, Stefan Michiels, Veerle Bossuyt, Federico Rojo, Baljit Singh, Torsten Nielsen, Giuseppe Viale, Seong-Rim Kim, Stephen Hewitt, Stephan Wienert, Sybille Loibl, David Rimm, Fraser Symmans, Carsten Denkert, Sylvia Adams, Sherene Loi, Roberto Salgado Morphological evaluation of tumor-infiltrating lymphocyt...
Source: Seminars in Cancer Biology - October 9, 2017 Category: Cancer & Oncology Source Type: research

Emerging targets in cancer immunotherapy
Publication date: Available online 5 October 2017 Source:Seminars in Cancer Biology Author(s): Samantha Burugu, Amanda R. Dancsok, Torsten O. Nielsen The first generation of immune checkpoint inhibitors (anti-CTLA-4 and anti-PD-1/PD-L1) targeted natural immune homeostasis pathways, co-opted by cancers, to drive anti-tumor immune responses. These agents led to unprecedented results in patients with previously incurable metastatic disease and may become first-line therapies for some advanced cancers. However, these agents are efficacious in only a minority of patients. Newer strategies are becoming available that target add...
Source: Seminars in Cancer Biology - October 8, 2017 Category: Cancer & Oncology Source Type: research

Targeting receptor tyrosine kinase EphB4 in cancer therapy
Publication date: Available online 6 October 2017 Source:Seminars in Cancer Biology Author(s): Yinnan Chen, Hongmei Zhang, Yanmin Zhang Eph receptors and their Eph receptor-interacting (ephrin) ligands together form an important cell communication system with diverse roles. Experimental evidence demonstrated Eph receptor bidirectional signaling with both tumor-suppressing and tumor-promoting activities in cancer cells. The tyrosine kinase EphB4, a member of the Eph receptor family, has been associated with tumor angiogenesis, growth and metastasis, thus making it a valuable and attractive target for drug design for therap...
Source: Seminars in Cancer Biology - October 7, 2017 Category: Cancer & Oncology Source Type: research

Epigenetics in myelodysplastic syndromes
Publication date: Available online 2 August 2017 Source:Seminars in Cancer Biology Author(s): Michael Heuser, Haiyang Yun, Felicitas Thol Epigenetic regulators are the largest group of genes mutated in MDS patients. Most mutated genes belong to one of three groups of genes with normal functions in DNA methylation, in H3K27 methylation/acetylation or in H3K4 methylation. Mutations in the majority of epigenetic regulators disrupt their normal function and induce a loss-of-function phenotype. The transcriptional consequences are often failure to repress differentiation programs and upregulation of self-renewal pathways. Howe...
Source: Seminars in Cancer Biology - September 28, 2017 Category: Cancer & Oncology Source Type: research

Epigenetics in Multiple Myeloma: From Mechanisms to Therapy
Publication date: Available online 27 September 2017 Source:Seminars in Cancer Biology Author(s): Mohammad Alzrigat, Alba Atienza Párraga, Helena Jernberg-Wiklund Multiple myeloma (MM) is a tumor of antibody producing plasmablasts/plasma cells that resides within the bone marrow (BM). In addition to the well-established role of genetic lesions and tumor-microenvironment interactions in the development of MM, deregulated epigenetic mechanisms are emerging as important in MM pathogenesis. Recently, MM sequencing and expression projects have revealed that mutations and copy number variations as well as deregulation in...
Source: Seminars in Cancer Biology - September 28, 2017 Category: Cancer & Oncology Source Type: research

FOXO1: another avenue for treating digestive malignancy?
Publication date: Available online 28 September 2017 Source:Seminars in Cancer Biology Author(s): Feiyu Shi, Tian Li, Zhi Liu, Kai Qu, Chengxin Shi, Yaguang Li, Qian Qin, Liang Cheng, Xin Jin, Tianyu Yu, Wencheng Di, Jianwen Que, Hongping Xia, Junjun She Digestive malignancies are the leading cause of mortality among all neoplasms, contributing to estimated 3 million deaths in 2012 worldwide. The mortality rate hassurpassed lung cancer and prostate cancer in recent years. The transcription factor Forkhead Box O1 (FOXO1) is a key member of Forkhead Box family, regulating diverse cellular functions during tumor initiation, ...
Source: Seminars in Cancer Biology - September 28, 2017 Category: Cancer & Oncology Source Type: research

Impact of DNA Methylation Programming on Normal and Pre-leukemic Hematopoiesis
Publication date: Available online 28 September 2017 Source:Seminars in Cancer Biology Author(s): Jens Langstein, Michael D. Milsom, Daniel B. Lipka Epigenome regulation is a critical mechanism that governs cell identity, lineage specification and developmental cell fates. With the advent of low-input and single-cell technologies as well as sophisticated cell labeling techniques, our understanding of transcriptional and epigenetic regulation of hematopoiesis is currently undergoing dramatic changes. Increasingly, evidence suggests that the epigenome conformation acts as a critical decision-making mechanism that instructs ...
Source: Seminars in Cancer Biology - September 28, 2017 Category: Cancer & Oncology Source Type: research

The Society for Immunotherapy of Cancer Biomarkers Task Force Recommendations Review
Publication date: Available online 22 September 2017 Source:Seminars in Cancer Biology Author(s): Lisa H. Butterfield The clinical successes in cancer immunotherapy have led to a critical need for biomarkers in cancer immunotherapy. It is of the utmost importance to know who is most likely to benefit from these therapies (predictive biomarkers) but also who is starting to respond (prognostic biomarkers) and how the therapy functions in order to make rational combination choices (mechanism of action biomarkers). The Society for Immunotherapy of Cancer (SITC) Biomarkers Task Force addressed the state of the art and made a s...
Source: Seminars in Cancer Biology - September 22, 2017 Category: Cancer & Oncology Source Type: research

Lung cancer epigenetics: from knowledge to applications
Publication date: Available online 14 September 2017 Source:Seminars in Cancer Biology Author(s): Michaël Duruisseaux, Manel Esteller Lung cancer is the leading cause of cancer-related mortality worldwide. Advances in our understanding of the genomics of lung cancer have led to substantial progress in the treatment of specific molecular subsets. Immunotherapy also emerges as a major breakthrough in lung cancer treatment. However, challenges remain as a consensual approach for early lung cancer detection remains elusive while primary or secondary drug resistance eventually leads to treatment failure in all patients wi...
Source: Seminars in Cancer Biology - September 15, 2017 Category: Cancer & Oncology Source Type: research

Emerging biomarkers for cancer immunotherapy in melanoma
Publication date: Available online 14 September 2017 Source:Seminars in Cancer Biology Author(s): Margaret L. Axelrod, Douglas B. Johnson, Justin M. Balko The treatment and prognosis of metastatic melanoma has changed substantially since the advent of novel immune checkpoint inhibitors (ICI), agents that enhance the anti-tumor immune response. Despite the success of these agents, clinically actionable biomarkers to aid patient and regimen selection are lacking. Herein, we summarize and review the evidence for candidate biomarkers of response to ICIs in melanoma. Many of these candidates can be examined as parts of a known...
Source: Seminars in Cancer Biology - September 14, 2017 Category: Cancer & Oncology Source Type: research

EMT, inflammation and metastasis
Publication date: Available online 12 September 2017 Source:Seminars in Cancer Biology Author(s): C. Theresa Vincent, Jonas Fuxe (Source: Seminars in Cancer Biology)
Source: Seminars in Cancer Biology - September 13, 2017 Category: Cancer & Oncology Source Type: research

MAPK Signalling Pathway in Cancers: Olive Products as Cancer Preventive and Therapeutic Agents
Publication date: Available online 11 September 2017 Source:Seminars in Cancer Biology Author(s): Ilaria Peluso, Nagendra Sastry Yarla, Roberto Ambra, Gianni Pastore, George Perry The mitogen-activated protein kinases (MAPKs) are fundamental in inflammation and cancer control, through the crosstalk between the redox regulated nuclear factor E2-related factor 2 (Nrf2) and nuclear factor-kB (NFκB) gene expression. MAPKs regulate various cellular activities involved in cancer progression, including proliferation, apoptosis and immune escape and blockade of upstream kinases is a current therapeutic strategy. However, th...
Source: Seminars in Cancer Biology - September 11, 2017 Category: Cancer & Oncology Source Type: research

Epigenetics in pediatric acute lymphoblastic leukemia
Publication date: Available online 5 September 2017 Source:Seminars in Cancer Biology Author(s): Jessica Nordlund, Ann-Christine Syvänen Acute lymphoblastic leukemia (ALL) is the most common malignancy in children. ALL arises from the malignant transformation of progenitor B- and T-cells in the bone marrow into leukemic cells, but the mechanisms underlying this transformation are not well understood. Recent technical advances and decreasing costs of methods for high-throughput DNA sequencing and SNP genotyping have stimulated systematic studies of the epigenetic changes in leukemic cells from pediatric ALL patients. ...
Source: Seminars in Cancer Biology - September 6, 2017 Category: Cancer & Oncology Source Type: research

Prognostic and Predictive Biomarkers in Breast Cancer: Past, Present and Future
Publication date: Available online 4 September 2017 Source:Seminars in Cancer Biology Author(s): Andrea Nicolini, Paola Ferrari, Michael J. Duffy Following a diagnosis of breast cancer, the most immediate challenges in patient management are the determination of prognosis and identification of the most appropriate adjuvant systemic therapy. Determining prognosis can best be addressed with a combination of traditional clinicopathological prognostic factors, biomarkers such as HER2/neu and specific multigene genes tests. Amongst the best validated prognostic multigene tests are uPA/PAI1, Oncotype DX and MammaPrint. Oncotype...
Source: Seminars in Cancer Biology - September 5, 2017 Category: Cancer & Oncology Source Type: research

Optomechanical devices for Deep Plasma Cancer Proteomics
Publication date: Available online 1 September 2017 Source:Seminars in Cancer Biology Author(s): Priscila M. Kosaka, Montserrat Calleja, Javier Tamayo Most of the cancer deaths could be avoided by early detection of the tumor when it is confined to its primary site and it has not metastasized. To this aim, one of the most promising strategies is the discovery and detection of protein biomarkers shed by the young tumor to the bloodstream. Proteomic technologies, mainly mass spectrometry and multiplexed immunoassays, have rapidly developed during last years with improved limits of detection and multiplexing capability. Unfo...
Source: Seminars in Cancer Biology - September 2, 2017 Category: Cancer & Oncology Source Type: research

Phosphatidylserine: A cancer cell targeting biomarker
Publication date: Available online 1 September 2017 Source:Seminars in Cancer Biology Author(s): Bhupender Sharma, Shamsher S. Kanwar Cancer is a leading cause of mortality and morbidity globally. Many prominent cancer-associated molecules have been identified over the recent years which include EGFR, CD44, TGFbRII, HER2, miR-497, NMP22, BTA, Fibrin/FDP etc. These biomarkers are often used for screening, detection, diagnosis, prognosis, prediction and monitoring of cancer development. Phosphatidylserine (PS) is an essential component in all human cells which is present on the inner leaflet of the cell membrane. The oxidat...
Source: Seminars in Cancer Biology - September 2, 2017 Category: Cancer & Oncology Source Type: research

Inflammation fires up cancer metastasis
Publication date: Available online 31 August 2017 Source:Seminars in Cancer Biology Author(s): Bin-Zhi Qian Metastatic disease is the major challenge of cancer that accounts for over 90% of total cancer lethality. Mounting clinical and preclinical data now indicate that inflammation, a potent immune and repair response, is indispensable for metastasis. In this review we describe our current understanding of how major inflammatory cells contribute to metastatic cascade with a focus on the primary tumour. We also discuss exciting new directions for future research and novel therapeutic approaches to tackle metastatic diseas...
Source: Seminars in Cancer Biology - September 1, 2017 Category: Cancer & Oncology Source Type: research

FoxM1: Repurposing an Oncogene as a Biomarker
Publication date: Available online 30 August 2017 Source:Seminars in Cancer Biology Author(s): Deeptashree Nandi, Pradeep Singh Cheema, Neha Jaiswal, Alo Nag The past few decades have witnessed a tremendous progress in understanding the biology of cancer, which has led to more comprehensive approaches for global gene expression profiling and genome-wide analysis. This has helped to determine more sophisticated prognostic and predictive signature markers for the prompt diagnosis and precise screening of cancer patients. In the search for novel biomarkers, there has been increased interest in FoxM1, an extensively studied t...
Source: Seminars in Cancer Biology - August 31, 2017 Category: Cancer & Oncology Source Type: research

Charting the dynamic epigenome during B-cell development
Publication date: Available online 26 August 2017 Source:Seminars in Cancer Biology Author(s): Jose I. Martin-Subero, Christopher C. Oakes The epigenetic landscape undergoes a widespread modulation during embryonic development and cell differentiation. Within the hematopoietic system, B cells are perhaps the cell lineage with a more dynamic DNA methylome during their maturation process, which involves approximately one third of all the CpG sites of the genome. Although each B-cell maturation step displays its own DNA methylation fingerprint, the DNA methylome is more extensively modified in particular maturation transitio...
Source: Seminars in Cancer Biology - August 27, 2017 Category: Cancer & Oncology Source Type: research

Probiotic species in the modulation of the anticancer immune response
Publication date: Available online 24 August 2017 Source:Seminars in Cancer Biology Author(s): Luciana Marinelli, Gian Carlo Tenore, Ettore Novellino Mounting evidences are supporting a key role of distinct gut bacteria in the occurrence and progression of intestinal and extra-intestinal tumors. More importantly, it has been recently demonstrated that some gut bacteria strains synergize with largely-used anticancer drugs as alkylating or immune checkpoint blockade agents thus optimizing the immune response against multiple solid cancers. However, the exact role played by each gut bacterium in cancer occurrence and respons...
Source: Seminars in Cancer Biology - August 25, 2017 Category: Cancer & Oncology Source Type: research

In vitro polyphenol effects on apoptosis: an update of literature data
Publication date: Available online 19 August 2017 Source:Seminars in Cancer Biology Author(s): Valeria Curti, Arianna Di Lorenzo, Marco Dacrema, Jianbo Xiao, Sayed Mohammad Nabavi, Maria Daglia Polyphenols are secondary plant metabolites which have been studied extensively for their health-promoting properties, and which could also exert pharmacological activities ranging from anti-inflammatory effects, to cytotoxic activity against cancer cells. The main mechanism for programmed cell death is represented by apoptosis, and its dysregulation is involved in the etiopathology of cancer. As such, substances able to induce apo...
Source: Seminars in Cancer Biology - August 20, 2017 Category: Cancer & Oncology Source Type: research

Epithelial-mesenchymal transition and inflammation at the site of the primary tumor
Publication date: Available online 18 August 2017 Source:Seminars in Cancer Biology Author(s): Charli Dominguez, Justin M. David, Claudia Palena Tumor growth and progression are the products of complex signaling networks between different cell types within the tumor and its surrounding stroma. In particular, established tumors are known to stimulate an inflammatory reaction via the secretion of cytokines, chemokines, and growth factors that favor the recruitment of a range of infiltrating immune cell populations into the tumor microenvironment. While potentially able to exert tumor control, this inflammatory reaction is t...
Source: Seminars in Cancer Biology - August 18, 2017 Category: Cancer & Oncology Source Type: research

The receptor for advanced glycation end products: A fuel to pancreatic cancer
Publication date: Available online 12 August 2017 Source:Seminars in Cancer Biology Author(s): Uzma Shahab, Mohd. Kaleem Ahmad, Abbas Ali Mahdi, Mohd. Waseem, Binish Arif, Moinuddin, Saheem Ahmad The receptor for advanced glycation end products (RAGEs) was first illustrated in the year 1992. RAGE is a single-transmembrane and multi-ligand component of the immunoglobulin protein super family. The engagement of RAGE turns out to an establishment of numerous intracellular signalling mechanisms resulting in the progression and perpetuation of many types of cancer including, the pancreatic cancer. The present review primarily ...
Source: Seminars in Cancer Biology - August 17, 2017 Category: Cancer & Oncology Source Type: research

Epigenetic drivers of tumourigenesis and cancer metastasis
Publication date: Available online 12 August 2017 Source:Seminars in Cancer Biology Author(s): Aniruddha Chatterjee, Euan J. Rodger, Michael R. Eccles Since the completion of the first human genome sequence and the advent of next generation sequencing technologies, remarkable progress has been made in understanding the genetic basis of cancer. These studies have mainly defined genetic changes as either causal, providing a selective advantage to the cancer cell (a driver mutation) or consequential with no selective advantage (not directly causal, a passenger mutation). A vast unresolved question is how a primary cancer cel...
Source: Seminars in Cancer Biology - August 17, 2017 Category: Cancer & Oncology Source Type: research

Regulation of Cell Signaling Pathways by Dietary Agents for Cancer Prevention and Treatment
Publication date: Available online 16 August 2017 Source:Seminars in Cancer Biology Author(s): Manoj K. Pandey, Subash C. Gupta, Ali Nabavizadeh, Bharat B. Aggarwal Although it is widely accepted that better food habits do play important role in cancer prevention and treatment, how dietary agents mediate their effects remains poorly understood. More than thousand different polyphenols have been identified from dietary plants. In this review, we discuss the underlying mechanism by which dietary agents can modulate a variety of cell-signaling pathways linked to cancer, including transcription factors, nuclear factor κ...
Source: Seminars in Cancer Biology - August 17, 2017 Category: Cancer & Oncology Source Type: research

Mechanisms that drive inflammatory tumor microenvironment, tumor heterogeneity, and metastatic progression
Publication date: Available online 3 August 2017 Source:Seminars in Cancer Biology Author(s): Li Yang, P. Charles Lin Treatment of cancer metastases has been largely ineffective. It is paramount to understand the mechanisms underlying the metastatic process, of which the tumor microenvironment is an indispensable participant. What are the critical cellular and molecular players at the primary tumor site where metastatic cascade initiates? How is tumor-associated inflammation regulated? How do altered vasculatures contribute to metastasis? What is the dynamic nature or heterogeneity of primary tumors and what are the chall...
Source: Seminars in Cancer Biology - August 4, 2017 Category: Cancer & Oncology Source Type: research

Epigenetics in Ovarian Cancer
Publication date: Available online 3 August 2017 Source:Seminars in Cancer Biology Author(s): Yanina Natanzon, Ellen L. Goode, Julie M. Cunningham Ovarian cancer is a disease with a poor prognosis and little progress has been made to improve treatment. It is now recognized that there are several histotypes of ovarian cancer, each with distinct epidemiologic and genomic characteristics. Cancer therapy is moving beyond classical chemotherapy to include epigenetic approaches. Epigenetics is the dynamic regulation of gene expression by DNA methylation and histone post translational modification in response to environmental cu...
Source: Seminars in Cancer Biology - August 4, 2017 Category: Cancer & Oncology Source Type: research

Novel epigenetic therapies in hematological malignancies: current status and beyond
Publication date: Available online 4 August 2017 Source:Seminars in Cancer Biology Author(s): Paolo Gallipoli, Brian J.P. Huntly Over the last decade transcriptional dysregulation and altered epigenetic programs have emerged as a hallmark in the majority of hematological cancers. Several epigenetic regulators are recurrently mutated in many hematological malignancies. In addition, in those cases that lack epigenetic mutations, altered function of epigenetic regulators has been shown to play a central role in the pathobiology of many hematological neoplasms, through mechanisms that are becoming increasingly understood. Thi...
Source: Seminars in Cancer Biology - August 4, 2017 Category: Cancer & Oncology Source Type: research

Epigenetics in MDS
Publication date: Available online 2 August 2017 Source:Seminars in Cancer Biology Author(s): Michael Heuser, Haiyang Yun, Felicitas Thol Epigenetic regulators are the largest group of genes mutated in MDS patients. Most mutated genes belong to one of three groups of genes with normal functions in DNA methylation, in H3K27 methylation/acetylation or in H3K4 methylation. Mutations in the majority of epigenetic regulators disrupt their normal function and induce a loss-of-function phenotype. The transcriptional consequences are often failure to repress differentiation programs and upregulation of self-renewal pathways. Howe...
Source: Seminars in Cancer Biology - August 2, 2017 Category: Cancer & Oncology Source Type: research

Epigenetic dysregulation in chronic myeloid leukaemia: A myriad of mechanisms and therapeutic options
Publication date: Available online 2 August 2017 Source:Seminars in Cancer Biology Author(s): Steffen Koschmieder, David Vetrie The onset of global epigenetic changes in chromatin that drive tumor proliferation and heterogeneity is a hallmark of many forms cancer. Identifying the epigenetic mechanisms that govern these changes and developing therapeutic approaches to modulate them, is a well-established avenue pursued in translational cancer medicine. Chronic myeloid leukemia (CML) arises clonally when a hematopoietic stem cell (HSC) acquires the capacity to produce the constitutively active tyrosine kinase BCR-ABL1 fusio...
Source: Seminars in Cancer Biology - August 2, 2017 Category: Cancer & Oncology Source Type: research

Current and Emerging Biomarkers in Tumors of the Central Nervous System: Possible Diagnostic, Prognostic and Therapeutic Applications
Publication date: Available online 31 July 2017 Source:Seminars in Cancer Biology Author(s): Ishaq N. Khan, Najeeb Ullah, Deema Hussein, Kulvinder S. Saini Recent investments in research associated with the discovery of specific tumor biomarkers important for efficient diagnosis and prognosis of the patients are beginning to bear fruit. Key biomarkers could potentially outweigh traditional radiological or pathological methods by enabling specificity of early detection, when coupled with tumor molecular profiling and clinical associations. Only few biomarkers are approved by regulatory authorities for Central Nervous Syste...
Source: Seminars in Cancer Biology - August 1, 2017 Category: Cancer & Oncology Source Type: research

FOXO in B-cell lymphopoiesis and B cell neoplasia
Publication date: Available online 31 July 2017 Source:Seminars in Cancer Biology Author(s): Alexey Ushmorov, Thomas Wirth FOX O family transcription factors are important for differentiation and function of multiple cell types. In B lymphocytes they play a critical role. The activity of FOXOs is directly regulated both by signaling from B cell receptor (BCR) and cytokine receptors. FOXO1 action controls the transition between differentiation stages of B cell development. In comparison to other FOXO family members, FOXO1 plays a superior role in the regulation of early stages of B-cell differentiation. Although being know...
Source: Seminars in Cancer Biology - August 1, 2017 Category: Cancer & Oncology Source Type: research

Role of Forkhead Box Class O proteins in cancer progression and metastasis
Publication date: Available online 1 August 2017 Source:Seminars in Cancer Biology Author(s): Chang Geun Kim, Hyemin Lee, Nehal Gupta, Sharavan Ramachandran, Itishree Kaushik, Sangeeta Srivastava, Sung-Hoon Kim, Sanjay K. Srivastava It is now widely accepted that several gene alterations including transcription factors are critically involved in cancer progression and metastasis. Forkhead Box Class O proteins (FoxOs) including FoxO1/FKHR, FoxO3/FKHRL1, FoxO4/AFX and FoxO6 transcription factors are known to play key roles in proliferation, apoptosis, metastasis, cell metabolism, aging and cancer biology through their phosp...
Source: Seminars in Cancer Biology - August 1, 2017 Category: Cancer & Oncology Source Type: research

Bacterial infection increases risk of carcinogenesis by targeting mitochondria
Publication date: Available online 25 July 2017 Source:Seminars in Cancer Biology Author(s): Jesper A.B. Strickertsson, Claus Desler, Lene Juel Rasmussen As up to a fifth of all cancers worldwide, have now been linked to microbial infections, it is essential to understand the carcinogenic nature of the bacterial/host interaction. This paper reviews the bacterial targeting of mediators of mitochondrial genomic fidelity and of mitochondrial apoptotic pathways, and compares the impact of the bacterial alteration of mitochondrial function to that of cancer. Bacterial virulence factors have been demonstrated to induce mutation...
Source: Seminars in Cancer Biology - July 27, 2017 Category: Cancer & Oncology Source Type: research

AGEs, RAGEs and s-RAGE; friend or foe for cancer
This article is an insightful assessment on AGE, RAGE and s-RAGE for its possible role in cancer onset and progression. The novel therapeutic targets for cancer prevention or inhibition are also explained in brief in relation to AGE and RAGE. (Source: Seminars in Cancer Biology)
Source: Seminars in Cancer Biology - July 15, 2017 Category: Cancer & Oncology Source Type: research